Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 12/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15610575 | 0.89 | CHRM3 (0.47) | CHRM3CHRM2ACHECHRNA7SLC18A3 | |
| SCHEMBL10265766 | 0.79 | CHRM3 (0.49) | CHRM3CHRM2ACHECHRNA7SLC18A3 | |
| SCHEMBL10256418 | 0.75 | CHRM3 (0.50) | CHRM3CHRM2ACHESLC18A3 | |
| SCHEMBL10256701 | 0.73 | ACHE (0.43) | CHRM3CHRM2ACHECHRNA7 | |
| SCHEMBL12160731 | 0.72 | ACHE (0.48) | CHRM3ACHESLC18A3 | |
| SCHEMBL15624979 | 0.72 | CHRNA7 (0.39) | ACHECHRNA7CHRNB4CHRNA3 | |
| SCHEMBL17069874 | 0.72 | CHRM3 (0.45) | CHRM3CHRM2ACHE | |
| SCHEMBL5863171 | 0.72 | ACHE (0.51) | CHRM3CHRM2ACHE | |
| SCHEMBL3681307 | 0.71 | CHRNA7 (0.60) | CHRM3CHRM2ACHECHRNA7CHRNB4 | |
| Water SCHEMBL5859572 | 0.71 | ACHE (0.50) | CHRM3CHRM2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278313-B2 | Macrocyclic spiro pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | DPYD, TYMS, TYMP | CHRM3 4786/4885CHRM2 4848/4885ACHE 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.